この論文をさがす
説明
Kato and colleagues ([1][1]) reported 4 cancer patients with metastatic disease, hyperprogression under treatment with anti-PD-1/PD-L1 monotherapy, and a cooccurring MDM2/4 amplification in the cancer cells. They defined hyperprogression as time-to-treatment failure 50% increase in tumor
収録刊行物
-
- Clinical Cancer Research
-
Clinical Cancer Research 23 6374-6375, 2017-10-12
American Association for Cancer Research (AACR)